Amgen Inc. (ETR:AMG)
Germany · Delayed Price · Currency is EUR | Market Cap | 195.57B +42.8% |
| Revenue (ttm) | 33.34B +9.1% |
| Net Income | 7.65B +32.1% |
| EPS | 14.09 +31.6% |
| Shares Out | n/a |
| PE Ratio | 25.56 |
| Forward PE | 17.18 |
| Dividend | 8.50 (2.37%) |
| Ex-Dividend Date | Aug 21, 2026 |
| Volume | 233 |
| Open | 364.85 |
| Previous Close | 367.95 |
| Day's Range | 357.50 - 366.75 |
| 52-Week Range | 247.65 - 383.05 |
| Beta | 0.43 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 5, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
Amgen price target raised to $500 from $450 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares. The firm notes Amgen’s execution has…
Amgen price target raised to $500 from $450 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares.
Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi
Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially underappreciated I&I asset.” However, several details th...
Amgen announces ‘positive’ results from Phase 3 OASIZ 301 study
Amgen (AMGN) announced positive topline results from the Phase 3 OASIZ 301 study evaluating dazodalibep in adults with Sjogren’s disease and moderate-to-severe systemic disease activity. The study met...
Amgen's autoimmune drug succeeds in late-stage trial
Amgen said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body's moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Dazodalibep Demonstrated Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity Results Support the Potential for a New, Highly Differentiated Treatment Option f...
Amgen Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Quarterly revenue exceeded $10 billion, driven by strong growth across key products and robust pipeline progress. Landmark clinical results and regulatory advances support future growth, while disciplined capital allocation and evolving DTC strategies position the business for long-term success.
Amgen to deploy Veeva Vault CRM globally
Veeva Systems (VEEV) announced that Amgen (AMGN) plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade. “Moving to Vault CRM will help accelerate…
Amgen says FDA approves update to imdelltra Prescribing Information
Amgen (AMGN) announced that the U.S. FDA approved an update to the imdelltra Prescribing Information that substantially reduces the recommended monitoring time for the first two doses of treatment in…
FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Update Supports Broader Access to IMDELLTRA in Community Settings for People Living with Extensive-Stage Small Cell Lung Cancer THOUSAND OAKS, Calif., Sept. 14, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN...
Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
Amgen Transcript: Wells Fargo 21st Annual Healthcare Conference
Quarterly revenues exceeded $10 billion, driven by strong growth across six key product areas and robust pipeline progress. Landmark clinical results for IMDELLTRA and TEZSPIRE, expanding biosimilar portfolio, and strategic focus on productivity and disciplined investment support a positive long-term outlook.
HSBC downgrades Amgen to Hold on fair value after re-rating
HSBC analyst Morten Herholdt last night downgraded Amgen (AMGN) to Hold from Buy with a price target of $425, down from $445. After re-rating on Amgen’s strong execution and positive…
Amgen downgraded to Hold from Buy at HSBC
HSBC downgraded Amgen (AMGN) to Hold from Buy with a price target of $425, down from $445.
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif., Sept. 9, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30 a.m.
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Amgen (AMGN) shares sold off after Novartis (NVS) failed to meet its primary endpoint in phase-3 trials. Diane King Hall offers more insight into the volatile moves in the healthcare space.
Amgen, AstraZeneca report Phase 3 DeLLphi-305 study met primary endpoint
Amgen (AMGN) announced results from the Phase 3 DeLLphi-305 study, which met its primary endpoint at a pre-specified interim analysis, demonstrating a statistically significant and clinically meaningf...
AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab
Positive high-level results from a planned interim analysis of the DeLLphi-305 Phase III trial showed IMFINZI plus Amgen’s (AMGN) tarlatamab demonstrated a statistically significant and highly clinica...
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Phase 3 DeLLphi-305 Study Delivered Highly Significant and Clinically Meaningful Overall Survival Benefit Versus Durvalumab Alone Study Also Met Secondary Progression-Free Survival and Objective Respo...
Intel, Amgen, Novartis, Bloom Energy, and More Stocks That Explain Today's Market
AI stocks rise despite the market's inflation worries, but Amgen falls following Swiss drugmaker Novartis' disappointing trial data.
Why Amgen Stock Is Dropping After Swiss Rival's Trial Setback
Big Pharma has been scrambling to restock its pipelines, so a disappointing readout can have a knock-on effect on other drugmakers.
Amgen downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Amgen (AMGN) to Market Perform from Outperform with an unchanged price target of $450. The firm cites valuation for the downgrade, saying Amgen’s commercial execution “is now…
Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.